Disc Medicine, Inc. (IRON) Dividend History

Company News

• Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

  Disc Medicine, a clinical-stage biopharmaceutical company, announced the pricing of its upsized public offering of common stock and pre-funded warrants, raising approximately $225.5 million. The company plans to use the proceeds to fund research, clinical development, and potential commercialization of its product candidates.

  GlobeNewswire Inc.
• Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

  Disc Medicine, a clinical-stage biopharmaceutical company, announced the grant of an inducement equity award to a new employee, including a stock option and a restricted stock unit award.

  GlobeNewswire Inc.
• Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

  Disc Medicine presented positive updates across its portfolio, including updates from ongoing clinical studies and new preclinical data supporting the use of its investigational agents in existing and additional indications.

  GlobeNewswire Inc.
• Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

  Disc Medicine announced positive feedback from its end-of-Phase 2 meeting with the FDA, supporting the regulatory path forward for bitopertin in EPP. The company plans to initiate the APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+, by mid-2025. The FDA agreed on the study design, including the potential for accelerated approval based on reduction of PPIX as a surrogate endpoint.

  GlobeNewswire Inc.
• Disc Medicine Announces Underwritten Offering of Common Stock

  WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share. The aggregate gross proceeds to Disc from this offering are expected to be approximately $178.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities being sold in the offering are being offered by Disc. The offering is expected to close on June 17, 2024, subject to the satisfaction of customary closing conditions.

  GlobeNewswire Inc.